The makers of Tylenol, Johnson & Johnson JNJ.N and Kenvue KVUE.N, were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug’s links to autism and attention deficit hyperactivity disorder.Paxton, a Republican, sued five weeks after Republican President Donald Trump said using Tylenol during pregnancy can cause autism in children. Trump is not a doctor, and his claim is unproven and not backed by scientific evidence. Johnson & Johnson sold Tylenol for more than s ...

Pharmaceutical Industry Trends - The article discusses Acetaminophen, Prozac, and Ozempic [1] - The article is from Forbes Daily [1] Social Media - The article was shared on Twitter [1]

Core Points - The Department of Health and Human Services (HHS) and the White House have shared a 2017 tweet from Tylenol, reigniting discussions about a potential link between the drug and autism in children [2][4] - Kenvue, the parent company of Tylenol, stated that the tweet was taken out of context and emphasized that acetaminophen is considered the safest pain reliever during pregnancy [3][4] - A recent study from the Icahn School of Medicine at Mount Sinai supports evidence of a link between prenatal acetaminophen use and increased risks of autism and ADHD, analyzing data from over 100,000 participants [5] Company Impact - Following the renewed controversy, Kenvue's stock experienced a significant decline, dropping over 11% in the past five days due to fears of potential litigation stemming from the discussions [6] - HHS Secretary Robert F. Kennedy Jr. announced plans for a nationwide campaign advising clinicians to prescribe the lowest effective dose of acetaminophen during pregnancy [7] - Kenvue's stock is currently showing a weak price trend across short, medium, and long-term periods, with a poor momentum ranking of 9.67% [7]

Autism Crisis & Prevalence - The report highlights a significant increase in autism rates, from 1 in 10,000 children a few decades ago to 1 in 31 overall, and 1 in 12 for boys in some areas [4][5] - Since 2000, autism rates have surged by more than 400% [5] Potential Causes & Risk Factors - The FDA will notify physicians that acetaminophen (Tylenol) use during pregnancy can be associated with an increased risk of autism [8][9] - The report suggests a potential link between vaccines and autism, advocating for separating the MMR vaccine and delaying the Hepatitis B vaccine until the child is 12 years old [16][18][19] - The report mentions that certain groups, like the Amish, who do not take vaccines or pills, have virtually no autism [7][8] Proposed Actions & Research - HHS is launching an all-agency effort to identify all causes of autism, including toxic and pharmaceutical exposures [27] - NIH will be announcing 13 major grant awards from the autism data science initiatives [21] - The FDA will be updating the label of an existing drug to reflect potential benefits in reducing some autism symptoms [19] Treatment & Prevention - The report suggests that spreading out vaccines over a longer period and in smaller doses may be beneficial [13][14] - The report emphasizes the importance of avoiding Tylenol during pregnancy unless medically necessary [10][11][12]

From @WSJopinion: The acetaminophen link to autism is based on weak evidence pushed by RFK Jr. and his legal allies. Donald Trump is raising public fear about a useful medicine in a way that could harm maternal and fetal health. https://t.co/QJTbFPJK3k ...

Pharmaceutical Safety & Regulation - Initial concerns arose from President Trump's warning about acetaminophen (Tylenol) use during pregnancy and a potential link to autism [1] - Industry research, including a study of approximately 250 万 (2.5 million) children in Sweden, suggests no definitive evidence of a link between acetaminophen use during pregnancy and autism [2][3] - Medical groups, such as obstetricians and gynecologists, maintain that Tylenol remains the best option for pregnant women needing pain and fever relief, citing risks associated with untreated fever and pain to the developing fetus [4] - Global health organizations and European regulators have also pushed back, indicating no current concern regarding acetaminophen use during pregnancy [4] Risk Assessment - Current scientific evidence suggests no significant risk or reason for concern regarding acetaminophen use during pregnancy [5]

Healthcare & Regulatory - FDA 将就怀孕期间使用对乙酰氨基酚与自闭症之间的联系向医生提供建议 [1]

FDA will advise doctors about link between autism, acetaminophen use during pregnancy, Trump sayshttps://t.co/P9jkQIRPu9 ...

Core Viewpoint - Ken View's stock has dropped over 7% to record lows due to reports linking Tylenol to autism risk during pregnancy, as suggested by the Trump administration [1][2] Company Analysis - Ken View's spokesperson asserts that independent science shows no causal link between acetaminophen and autism [2] - The upcoming remarks from President Trump are expected to address significant medical findings related to children's health [2] - The recent study referenced is a reanalysis of existing research from Harvard and Mount Sinai, not a new scientific study [3] - The study will also explore biological mechanisms that might explain the association between acetaminophen use and autism [4] - Concerns about potential bias exist, as two authors of the study are consultants for plaintiffs in recent litigation [4] Legal and Market Risks - The primary risk for Ken View is the potential for increased lawsuits, especially if new evidence emerges from the Trump administration's findings [5][6] - Previous litigation was dismissed due to lack of evidence, but it is currently in appeals [6] - Public opinion may pose a significant risk, potentially affecting consumer confidence and sales [7][9] Product Portfolio and Financial Impact - Tylenol is estimated to account for about 10% of Ken View's portfolio, making it a significant brand for the company [9] - There is speculation about potential asset sales, including the skin, health, and beauty segment, as well as Tylenol, to mitigate lawsuit risks [11][12] - Despite the current selloff, the stock is trading at lower levels than during previous litigation, suggesting it may be an attractive buying opportunity [14][15]

Core Viewpoint - A report by Health Secretary Robert F. Kennedy Jr. is expected to suggest a link between the use of acetaminophen (Tylenol) during pregnancy and an increased risk of autism, impacting Kenvue's stock performance [1][5]. Group 1: Report Findings - The upcoming report from the Department of Health and Human Services (HHS) will likely highlight insufficient folate levels and prenatal exposure to acetaminophen as potential contributing factors to autism [2]. - Research mentioned in the report indicates that a specific form of folate, folinic acid (leucovorin), may help alleviate autism-related symptoms [3]. - The report is anticipated to be published this month, with a focus on the implications of acetaminophen use during pregnancy [2]. Group 2: Company Response - Following the news of the HHS findings, Kenvue's stock dropped approximately 14% [5]. - A spokesperson for Kenvue stated that the company prioritizes patient safety and maintains that there is no proven causal relationship between acetaminophen use in pregnancy and autism [6]. - Kenvue emphasizes its commitment to continuously evaluate scientific evidence regarding the safety of its products [6]. Group 3: Industry Context - The American College of Obstetricians and Gynecologists currently considers acetaminophen safe for use during pregnancy, advising that it should be taken under medical guidance [4]. - The HHS is also set to announce new federal grants to support autism research as part of the National Institutes of Health's broader data science program [7].